Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Total Liabilities (2016 - 2026)

Ekso Bionics Holdings has reported Total Liabilities over the past 14 years, most recently at $11.1 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 20.52% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.1 million, a 20.52% decrease, with the full-year FY2025 number at $11.1 million, down 20.52% from a year prior.
  • Total Liabilities reached $11.1 million in Q4 2025 per EKSO's latest filing, down from $12.0 million in the prior quarter.
  • The five-year high for Total Liabilities was $16.3 million in Q4 2023, with the low at $8.8 million in Q2 2022.
  • The 5-year median for Total Liabilities is $14.1 million (2024), against an average of $13.5 million.
  • Peak YoY movement for Total Liabilities: skyrocketed 45889.29% in 2021, then plummeted 31.73% in 2022.
  • Tracing EKSO's Total Liabilities over 5 years: stood at $11.9 million in 2021, then rose by 29.41% to $15.5 million in 2022, then rose by 5.5% to $16.3 million in 2023, then fell by 14.51% to $13.9 million in 2024, then dropped by 20.52% to $11.1 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $11.1 million, $12.0 million, and $12.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.